Aclaris Therapeutics, Inc. SEC filings ACRS

Aclaris Therapeutics, Inc. has 872 filings in SEC EDGAR's recent list, going back to Sep 10, 2012. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 23, 2026 Dec 31, 2025
10-K Annual report Feb 26, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 24, 2025 Dec 31, 2024
10-K Annual report Feb 27, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 25, 2024 Dec 31, 2023
10-K Annual report Feb 27, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 20, 2023 Dec 31, 2022
10-K Annual report Feb 23, 2023 Dec 31, 2022
10-K Annual report Feb 24, 2022 Dec 31, 2021
10-K Annual report Feb 25, 2021 Dec 31, 2020
10-K Annual report Feb 25, 2020 Dec 31, 2019
10-K Annual report Mar 18, 2019 Dec 31, 2018
10-K Annual report Mar 12, 2018 Dec 31, 2017
10-K Annual report Mar 15, 2017 Dec 31, 2016
10-K/A Amended annual report Apr 25, 2016 Dec 31, 2015
10-K Annual report Mar 23, 2016 Dec 31, 2015

Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ACRS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Wayne, PA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1557746

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.